mitomycin has been researched along with medroxyprogesterone acetate in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC | 2 |
| Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K | 1 |
| Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y | 1 |
| Hirai, T; Iino, Y; Ishida, T; Izuo, M; Kawai, T; Ogawa, T; Suzuki, H; Yokoe, T | 1 |
| Falkson, CI; Falkson, G; Falkson, HC | 1 |
| Schroeder, FH | 1 |
| Nomura, Y; Shirouzu, M; Takayama, T; Tashiro, H | 1 |
| Denis, L | 1 |
| Asada, Y; Fujisawa, K; Iida, Y; Kasahara, Y; Mitsui, T; Miura, S; Munemoto, Y; Ohata, K; Saito, H | 1 |
1 review(s) available for mitomycin and medroxyprogesterone acetate
| Article | Year |
|---|---|
[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Medroxyprogesterone Acetate; Methotrexate; Middle Aged; Mitomycin; Prednisolone; Vincristine | 1996 |
6 trial(s) available for mitomycin and medroxyprogesterone acetate
| Article | Year |
|---|---|
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Middle Aged; Mitomycin; Neoplasm Metastasis; Pilot Projects | 1992 |
High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Mitomycin; Mitomycins; Random Allocation; Vindesine | 1988 |
Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Topics: Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Estramustine; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Mitomycin; Mitomycins; Procarbazine; Prostatic Neoplasms; Random Allocation; Vinblastine; Vindesine | 1984 |
A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival Analysis | 1993 |
[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Medroxyprogesterone Acetate; Methotrexate; Middle Aged; Mitomycin; Prednisolone; Vincristine | 1996 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Castration; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Epirubicin; Estramustine; Flutamide; Humans; Imidazoles; Male; Medroxyprogesterone Acetate; Methotrexate; Mitomycin; Neoplasms, Hormone-Dependent; Procarbazine; Prostatic Neoplasms; Vindesine | 1998 |
5 other study(ies) available for mitomycin and medroxyprogesterone acetate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Floxuridine; Humans; Liver Neoplasms; Lymphatic Metastasis; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Mitomycin; Mitomycins; Remission Induction | 1991 |
[Clinical efficacy of ifosfamide for liver metastasis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Ifosfamide; Liver Neoplasms; Medroxyprogesterone; Medroxyprogesterone Acetate; Mitomycin; Mitomycins; Sodium; Sodium Bicarbonate | 1990 |
[An analysis of treatments of recurrent breast cancer in relation to the lesion].
Topics: Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Humans; Lymphatic Metastasis; Medroxyprogesterone; Medroxyprogesterone Acetate; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Tamoxifen | 1985 |
Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colonic Neoplasms; Complement C3; Complement C4; Female; Fluorouracil; Humans; Immunotherapy; Lymphocyte Activation; Male; Medroxyprogesterone Acetate; Melphalan; Middle Aged; Mitomycin; Multivariate Analysis; Neoplasm Proteins; Phytohemagglutinins; Prognosis; Proportional Hazards Models; Proteoglycans; Pyrimidines; Time Factors; Treatment Outcome | 2004 |